08:37 AM EDT, 09/02/2025 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Tuesday that a substudy evaluating its Varipulse platform for pulsed field ablation procedures for atrial fibrillation demonstrated a "strong" safety profile, a 99.7% acute effectiveness, and procedural efficiency among 791 patients.

The company said that the Varipulse platform, which consists of the Varipulse catheter and Trupulse generator, integrates with the Carto system to enable a reproducible workflow that optimizes outcomes for atrial fibrillation treatment.

Johnson & Johnson ( JNJ ) said it will continue collaborating with the clinical community to expand real-world evidence for Varipulse and expedite innovation in atrial fibrillation care.